Homocysteine and polymorphisms of cystathionine synthase and methylentetrahydrofolate reductase in a healthy population from Colombia;Homocisteína polimorfismos de cistationina β sintasa y metilentetrahidrofolato reductasa en población sana de Colombia

Colombia Medica

Volumn 37, Issue 1, 2006, Pages 46-52

  Bermúdez, Marta ^a   Briceño, Ignacio ^a   Gil, Fabián ^a   Bernal, Jaime ^a  

^a PONTIFICIA UNIVERSIDAD JAVERIANA   (Colombia)

Author keywords

Cistationine sintase; Hyperhomocysteinemia; Metilenetetrahidrofolato reductasa; Polymorphisms; Vascular disease

Indexed keywords

CYSTATHIONINE BETA SYNTHASE; HOMOCYSTEINE; METHIONINE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2);

ARTICLE; COLOMBIA; ENZYME POLYMORPHISM; ETHNOLOGY; FEMALE; FISHER EXACT TEST; GENE FREQUENCY; GENETIC RISK; GENETIC VARIABILITY; GEOGRAPHIC DISTRIBUTION; HOMOZYGOSITY; HUMAN; HUMAN EXPERIMENT; HYPERHOMOCYSTEINEMIA; MALE; NORMAL HUMAN; RESTRICTION MAPPING; RISK ASSESSMENT; SEX DIFFERENCE; SOCIAL STATUS; STATISTICAL SIGNIFICANCE;

EID: 33646034644     PISSN: 16579534     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. The World Health Report 2002. Reducing risks, promoting healthy life. Geneva: WHO; 2002.
2. Woo KS, Chook P, Lolin YI, Cheung ASP, Chan LT, Sun YY, et al. Hyperhomocyst (e) inemia is a risk factor for arterial endothelial dysfunction in humans. Circulation 1997; 96: 2542-2544.
3. Graham IM, Daly LE, Refsum HM, Robinson K, Brattstrom LE Ueland PM, et al. Plasma homocysteine as a risk factor for vascular disease. JAMA 1997; 277: 1775-1781.
4. Mudd D, Levy HI, Kraus JP. Disorders of transsulphuration. En: Scriver C, Beaudet A, Sly W, Valle D (eds.). The metabolic and molecular bases of inherited disease. 8th ed. New York: McGraw Hill Inc.; 2001. p. 2007-2056.
5. 12 and folate. Am J Epidemiol 1996; 143: 845-859.
6. Refsum H. Ueland PM, Nygard O, Vollset SE. Homocysteine and cardiovascular disease. Annu Rev Med 1998; 49: 31-62.
7. Aras O, Hanson NQ, Yang F, Tsai MY. Influence of 699C-T and 1080C-T polymorphisms of the cystathionine B synthase gene on plasma homocysteine levels. Clin Genet 2000; 58: 455-459.
8. Sebastio G, Sperandeo MP, Panico M, Francis R, Kraus JP, Andria G. The molecular basis of homocystinuria due to cystathionine b synthase deficiency in Italian families, and report of four novel mutations. Am J Hum Genet 1995; 56: 1324-1333.
9. Tsai MY, Bignell M, Schwichtenberg K, Hanson NQ. High prevalence of a mutation in the cystathionine β-synthase gene. 0Am J Hum Genet 1996; 59: 1262-1267.
10. Kluijtmans LAJ, Boers GHJ, Verbruggen B, Trijbels FJM, Novàkovà IRO, Blom HJ. Homozygous cystathionine b synthase deficiency; combined with factor V leiden or thermolabile methylenetetrahidrofolate reductase in the risk of venous thrombosis. Blood 1996; 91: 2015-2018.
11. Franchis R, Fermo I, Mazzola G, Sebastio G, Di Minno G, Coppola A, et al. Contribution of the cystathionine b synthase gene (844ins68) polymorphism to the risk of early-onset venous and arterial occlusive disease and of fasting hyperhomocysteinemia. Thromb Haemost 2000; 84: 576-582.
12. Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews RG, et al. A candidate genetic risk factor for vascular disease: A common mutation in methylenetetrahidrofolate reductase. Nat Genet 1995; 10: 111-113.
13. Brattstrom L, Israelsson B, Norrving B, Bergqvist D, Thorne J, Hultberg B, et al. Impaired homocysteine metabolism in early-onset cerebral and peripheral occlusive arterial disease. Atherosclerosis 1990; 81: 51-60.
14. Boers GHJ, Smals AGH, Trijbels FJM, Fowler B, Bakkeren JAJM, Schoonderwaldt HC, et al. Heterozygosity for homocystinuria in premature peripheral and cerebral occlusive arterial disease. N Engl J Med 1985; 313: 709-715.
15. Bohórquez R, Isaza D. Diagnóstico y tratamiento del infarto agudo del miocardio. En: Texto de Cardiología. Bogotá: Sociedad Colombiana de Cardiología; 1999. p. 450-466.
16. Dudman NPB, Wilcken D, Wang J, Lynch JF, Macey D, Lundberg P. Disordered methionine/homocysteine metabolism in premature vascular disease. Arterioscler Thromb 1993; 13: 1253-1260.
17. Shipchandler MT, Moore EG. Rapid, fully automated measurement of plasma homocyst (e) ine with the Abbott IMx analyzer. Clin Chem 1995; 41: 991-994.
18. Lievers KJA, Kluijtmans LAJ, Heil SG, Boers GHJ, Verhoef P, Heijer M, et al. Cystathionine B-synthase polymorphisms and hyperhomocysteinemia: an association study. Eur J Hum Genet 2003; 11: 23-29.
19. Mutchinick OM, López MA, Luna L, Waxman J, Babinsky VE. High prevalence of the thermolabile methylenetetrahidrofolate reductase variant in Mexico: A country with a very high prevalence of neural tube defect. Mol Genet Metab 1999; 68: 461-467.
20. Casas JP, Bautista LE, Smeeth L, Sharma P, Hingorani AD. Homocysteine and stroke: evidence on a causal link from Mendelian randomisation. Lancet 2005; 365: 224-231.
21. Córdoba A., Arbeláez L, Castañeda S. Concentración plasmática de homocisteína en ayunas. Acta Med Colomb 2002; 27: 196-197.
22. Ubbink JB, Van der Merwe A, Delpot R, Allen RH, Stabler SP, Riezier R. The effect of a subnormal vitamin B-6 status on homocysteine metabolism. J Clin Invest 1996; 98: 177-184.
23. Bermúdez M, Frank N, Bernal J, Urreizti R, Briceño I, Merinero B, et al. High prevalence of CBS p.T191M mutation in homocystinuric patients from Colombia. Hum Mutat 2006; 27: 296-303.
24. Kolling K, Ndrepepa G, Werner K. Methylenetetrahidrofolate reductase gene C677T and A1298 C polymorphisms, plasma homocysteine, folate, and vitamin B12 levels and the extent of coronary artery disease. Am J Cardiol 2004; 93: 1201-1205.
25. Camacho O, Giusti B, Restrepo CM, Abbate R, Pepe G. Frequency of factor V (FV) Leiden and C677T methylenetetrahidrofolate reductase (MTHFR) mutations in Colombians. Thromb Haemost 1998; 79: 883-884.